Bridging scale-up to transplantation: pluripotent stem cell-derived pancreatic islet encapsulation in emulsion-generated high concentration alginate beads

Type 1 diabetes is a condition where the body's immune system mistakenly destroys the specific cells in the pancreas that produce insulin, a hormone essential for regulating blood sugar. Without these cells, people must rely on daily insulin injections to survive. For decades, scientists have searched for a way to replace these lost cells, hoping to restore the body's natural ability to manage glucose. One promising avenue involves creating new insulin-producing cells from stem cells, which are immature cells capable of turning into many different types of tissue. However, turning these stem cells into functional clusters that behave like natural pancreatic islets is only half the battle. To be useful for treating many patients, these cells must be grown in large quantities, a process that often causes them to clump together into massive, unhealthy blobs or get damaged by the movement required to keep them alive in a lab. Furthermore, once grown, these cells need protection from the patient's immune system to prevent rejection, a hurdle that usually requires patients to take strong, lifelong medication.

A team of researchers at McGill University has developed a new method to solve these problems simultaneously. They created a way to grow stem cell-derived islets inside tiny, protective spheres made of a natural substance called alginate, which is derived from seaweed. By placing the developing cells inside these spheres before they are fully mature, the researchers found they could grow them in large, stirred tanks without the cells sticking together or dying from the mechanical stress of the movement. More importantly, these protective spheres allowed the cells to survive and function for months after being transplanted into mice, all without the need for the animals to take immune-suppressing drugs. This work suggests a path toward a scalable manufacturing process that could eventually produce enough cells to treat many people with diabetes, while keeping the cells safe from the body's defenses.

The journey began with a specific challenge: how to grow stem cell-derived islets in large numbers. In the lab, these cells are typically grown in liquid suspension, where they are constantly moved to ensure they receive enough oxygen and nutrients. While this works for small batches, scaling up to the volumes needed for human therapy causes the cells to collide and fuse into giant, irregular clumps. These clumps become too large for nutrients to reach the center, leading to cell death. Additionally, the physical forces of stirring can damage the delicate cells. The researchers hypothesized that if they could encase each small cluster of cells in a protective shell early in the process, they could prevent them from fusing together and shield them from the harsh forces of large-scale bioreactors.

To test this, the team first grew human stem cells into clusters that were beginning to look like pancreatic islets. They then used a process involving oil and water to create thousands of tiny droplets, each containing a small group of cells suspended in a liquid alginate solution. By adding a specific chemical trigger, they turned these liquid droplets into solid, gel-like beads. They experimented with different strengths of the alginate gel, ranging from soft to quite stiff, to see how the environment affected the cells. They found that the cells survived well in all conditions, but the stiffness of the gel did influence the types of cells that developed. In the stiffer gels, the cells were more likely to become alpha cells, which produce a hormone called glucagon, while the softer environments and non-encapsulated groups produced more beta cells, the specific type needed to make insulin. Despite these differences, the cells in all groups remained capable of sensing sugar levels and releasing insulin when needed.

The most significant test came when the researchers moved these encapsulated cells into a 100-milliliter bioreactor, a small version of the large tanks used for industrial manufacturing. They grew the cells for 25 days, a period long enough to see if the protection held up. The results were striking. The non-encapsulated cells, left to float freely, grew into massive, fused clumps and suffered significant cell loss, with only about 60 percent of the original cells remaining. In contrast, the encapsulated cells stayed as distinct, uniform clusters, and 91 percent of them survived the extended culture period. The protective shells successfully prevented the cells from sticking together and shielded them from the physical stress of the stirring motion. This demonstrated that the method could be scaled up without losing the precious cells needed for therapy.

To see if these cells could actually work inside a living body, the researchers transplanted the encapsulated clusters into mice that had been genetically modified to lack an immune system, ensuring the cells would not be attacked. The mice received the cells directly into their abdominal cavity, a common site for such studies. The results showed that the cells began working almost immediately. Within a week, the mice started producing human C-peptide, a marker that indicates the transplanted cells were successfully making insulin. Over the next 98 days, the cells continued to function, responding to meals by releasing insulin and helping to regulate blood sugar levels. When the researchers examined the cells after three months, they found them to be healthy, viable, and still producing insulin, with no signs of the scar tissue or immune attack that often ruins such transplants.

This study provides a crucial link between the laboratory creation of stem cell therapies and their potential use in real-world medicine. By proving that these cells can be grown in large quantities, protected from damage, and transplanted successfully without immediate immune rejection, the researchers have addressed two of the biggest hurdles in the field. The method described is relatively simple and does not require complex, specialized equipment, making it a practical option for future manufacturing. While the cells did not produce as much insulin as those placed under the kidney capsule—a standard, highly vascularized site used for comparison—their ability to function for three months in the abdominal cavity is a major step forward. The work suggests that with further refinement, this approach could lead to a reliable, scalable way to produce the millions of cells needed to treat diabetes, offering a potential future where patients no longer need to rely on daily injections.